Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Decreases By 61.2%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 100,079 shares, a decline of 61.2% from the January 29th total of 258,211 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average trading volume of 372,176 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 372,176 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.6% of the company’s stock are short sold.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock opened at $1.41 on Thursday. The company has a 50-day moving average of $2.63 and a 200 day moving average of $5.01. The firm has a market cap of $9.73 million, a price-to-earnings ratio of -0.01 and a beta of -0.11. Revelation Biosciences has a 1 year low of $1.29 and a 1 year high of $46.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

Several large investors have recently made changes to their positions in REVB. Geode Capital Management LLC bought a new stake in shares of Revelation Biosciences in the 4th quarter worth approximately $27,000. Armistice Capital LLC bought a new position in Revelation Biosciences during the 3rd quarter valued at approximately $114,000. Finally, Sabby Management LLC raised its stake in Revelation Biosciences by 214.7% during the third quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock valued at $294,000 after buying an additional 141,262 shares during the last quarter. 12.80% of the stock is currently owned by hedge funds and other institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.